• Optimized hiPSC Differentiation for Functional Platelets

  2026-08-22

  This 2026 study develops an optimized differentiation scheme that increases megakaryocyte and platelet production from human induced pluripotent stem cells while shortening culture time and reducing cost. Its combination of embryoid-body optimization, human platelet lysate, and small-molecule modulation provides a practical framework for scalable platelet manufacturing, although broader validation is still needed.

• Angiotensin I/II (1-5): RAS Workflow Guide

  2026-08-22

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled cardiovascular and renal experiments involving the renin-angiotensin system. It is appropriate for hypertension research and related aldosterone or blood pressure assays, but should not be treated as a validated reagent for unrelated pathways, clinical use, or quantitative potency claims without additional evidence.

• Aneugen Molecular Mechanism Assay: Key Findings

  2026-08-21

  Bernacki and colleagues developed a tiered flow-cytometric strategy that distinguishes tubulin stabilization, tubulin destabilization, and mitotic kinase inhibition after detecting aneugenic activity. Its combination of fluorescent Taxol, phospho-histone H3, Ki-67, hierarchical clustering, and an artificial neural network offers a practical framework for moving beyond a binary genotoxicity result toward molecular interpretation.

• FGF4-FGFR1 Signaling in Diabetic Kidney Disease

  2026-08-20

  The reference study identifies podocyte-derived FGF4 as an endogenous protective factor in diabetic kidney disease and links its loss to worsening glomerular injury. Genetic deletion and recombinant-protein rescue experiments indicate that FGF4 acts through an FGFR1–AMPK–FOXO1 pathway to reduce oxidative stress, apoptosis, and podocyte loss in male mice.

• Carbapenemase Transmission in Guangdong CREC

  2026-08-20

  This 2025 BMC Microbiology study integrates carbapenemase-gene localization, conjugation testing, mobile-element analysis, and strain typing to examine carbapenem-resistant Enterobacter cloacae across eight teaching hospitals in Guangdong. Its findings show that blaNDM−1 was frequently plasmid-associated and readily transferable, emphasizing the value of combining resistance surveillance with transmission-focused laboratory analysis.

• PP 2 (AG 1879): Reliable Src Assay Design

  2026-08-19

  A scenario-based guide to using PP 2 (AG 1879), SKU A8216, in cell proliferation, viability, cytotoxicity, and signal-transduction workflows. It connects biochemical selectivity, solvent handling, concentration interpretation, and vendor-selection criteria to practical laboratory decisions.

• Pexidartinib (PLX3397) for TAM Assays

  2026-08-19

  Use Pexidartinib (PLX3397) as a controlled CSF1R perturbation tool to separate macrophage survival effects from direct tumor-cell responses. This workflow pairs CSF1R-mediated signaling inhibition with SPP1-focused phenotyping, enabling clearer interpretation of tumor microenvironment macrophage modulation in translational cancer research.

• 0.4% Trypan Blue Solution: Practical Cell Counting

  2026-08-18

  0.4% Trypan Blue Solution provides a simple endpoint method for cell viability measurement, cell counting, and live/dead cell discrimination in research cell suspensions. It is intended for scientific research workflows such as culture monitoring and cytotoxicity assays, but it should not be used as a diagnostic, medical, or standalone apoptosis and necrosis detection test.

• Thioredoxin Control of CHK1 Inhibitor Sensitivity

  2026-08-18

  The reference study identifies thioredoxin 1 as a determinant of checkpoint kinase 1 inhibitor sensitivity in non-small cell lung cancer. Its key mechanistic contribution is linking thioredoxin-dependent redox recycling of RRM1, ribonucleotide reductase activity, and deoxynucleotide availability, providing a rationale for combining CHK1 inhibitors with thioredoxin reductase inhibition.

• Palmitic Acid: Protocol and QC Guide

  2026-08-17

  Palmitic acid (SKU N2456), also called hexadecanoic acid, provides a characterized saturated long-chain fatty acid for controlled non-aqueous supplementation and lipid-focused research. It is suitable for metabolic, inflammatory, and signaling workflows when solvent controls and fresh preparations are used, but it is not appropriate for aqueous protocols or long-term solution storage.

• HOXC8, Caspase-1, and Pyroptosis in Lung Cancer

  2026-08-17

  The reference study identifies HOXC8 as a transcriptional suppressor of CASP1 that protects non-small cell lung carcinoma cells from caspase-1-driven pyroptosis. Its key contribution is linking HOXC8 to HDAC1/2 recruitment at the CASP1 promoter, providing a mechanistic explanation for how a developmental transcription factor can influence tumor cell survival and lung tumorigenesis.

• 15-PGDH Inhibition Supports Muscle Repair in Weight Loss

  2026-08-16

  A 2026 PNAS study identifies 15-PGDH inhibition as a strategy for improving muscle regeneration and force recovery during semaglutide-associated weight loss in obese mice. The work shows that combining a 15-PGDH inhibitor with semaglutide can improve postinjury muscle quality without negating weight-loss efficacy.

• TAK-242 (Resatorvid) TLR4 Workflow Guide

  2026-08-15

  Learn how to use TAK-242 as a mechanistic probe in LPS-challenged macrophages, NET–endothelial co-cultures, and neuroinflammation research. This guide emphasizes dosing logic, pathway-specific controls, assay timing, and troubleshooting for reproducible inflammatory signal pathway suppression.

• Sunitinib Beyond Angiogenesis: Metabolic Resensitization

  2026-08-14

  Sunitinib research is moving beyond vessel blockade toward adaptive-state biology. This thought-leadership analysis shows how metabolic intervention, causal rescue experiments, and biomarker-aligned workflows can clarify resistance in renal cell carcinoma models.

• Foretinib (GSK1363089) for Mechanism-Resolved Assays

  2026-08-14

  Foretinib (GSK1363089) is a potent ATP-competitive multikinase inhibitor for dissecting tumor cell growth, motility, invasion, and metastasis. This article applies endpoint-aware assay logic from cancer pharmacology research to help distinguish cytostatic effects from genuine cell killing.

11556 records 1/771 page Next 12345 下5页 Last page